Browsing: biotech women ceo

Facing a critical rise in gram-negative bacterial resistance, the health community confronts a formidable challenge, as these infections now rank…

Nabiha Saklayen, CEO of Cellino, was born in Saudi Arabia and raised partially in Germany and Sri Lanka. From a…

Amid the ongoing digitization of healthcare, digital therapeutics have gained popularity, with providers and payers increasingly offering these software-based therapies…

Almost two-thirds of Americans living with Alzheimer’s disease are women. Women in their 60’s are more than twice as likely…

Yaso Therapeutics gel technology takes aim at sperm before they can reach an egg, creating a non-hormonal contraceptive that prevents…

Treating cancer is complicated, lengthy, costly, and often significantly impacts the patient’s quality of life. What if there was a…

An estimated 71.5 million U.S. adults use wearable devices to collect biometric data, a measurement of various physical characteristics. Wearable…

Jurata Thin Film began as an idea to develop a novel way to deliver Ebola vaccines to low-income countries without…

Women have historically been denied the right to have a stake in the development of medical therapies targeting their health,…

Quantum computing has the potential to revolutionize how new drugs are developed. With the ability to take on challenges too…

A rare genetic respiratory disease affecting the tiny structures in the lungs that filter air is the target of promising…

Smart Immune is a clinical-stage biotechnology startup headquartered in France, developing a thymus-empowered T-cell therapy platform called ProTcell Platform. The…

Advanced neuroimaging techniques that can detect disease-linked proteins in the brain could be the key to quickly and accurately diagnosing…

Chronic kidney disease (CKD) affects more than 1 in 7 U.S. adults and approximately 2 in 1,000 Americans live with…

One company’s approach to breaking barriers within the TME to overcome recalcitrant cancers. Earlier this month, a preview of patient-derived…

Prostate cancer is the second most common form of cancer affecting men in the United States – 1 in 8 men will…

In 2021, Cognition Therapeutics completed two important clinical study trials. The first was SNAP which measured the displacement of amyloid beta oligomers into the cerebrospinal fluid (CSF). This study confirmed the mechanism of action of their lead candidate CT1812. CT1812 is orally delivered and designed to bind selectively to the sigma-2 receptor complex to restore damaged cellular processes. The second trial, SPARC, showed evidence that CT1812 slowed brain atrophy in mild-to-moderate Alzheimer patients. Currently, there are 7 ongoing clinical trials with CT1812. Cognition Therapeutics has also achieved over $117 million in funding from the National Institute on Aging. Lisa Ricciardi, CEO, and president of Cognition Therapeutics reported, “2021 was a transformative year for Cognition Therapeutics. We completed our IPO, secured significant additional non-dilutive funding, and progressed our pipeline creating a product portfolio in addition to our lead candidate CT1812.”

The emerging biotech scene in New York is refreshingly akin to the city’s eclectic metropolitan culture. The city’s liberal and…